DHP 1401

Drug Profile

DHP 1401

Alternative Names: DHP-1401

Latest Information Update: 04 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DAE HWA Pharmaceutical
  • Class
  • Mechanism of Action AMPA receptor modulators; Mitogen-activated protein kinase modulators; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 03 Feb 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by DAE HWA Pharmaceutical
  • 28 Dec 2016 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in South Korea (PO) (NCT03055741)
  • 01 Dec 2016 Preclinical trials in Alzheimer's disease in South Korea (PO), before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top